Target Name: MIR135B
NCBI ID: G442891
Review Report on MIR135B Target / Biomarker Content of Review Report on MIR135B Target / Biomarker
MIR135B
Other Name(s): hsa-mir-135b | mir-135b | hsa-miR-135b-5p | MIRN135B | MicroRNA 135b | microRNA 135b | hsa-miR-135b-3p

MIR135B: A Potential Drug Target and Biomarker for Obesity and Insulin Resistance

Obesity and insulin resistance are two of the leading causes of metabolic diseases, such as type 2 diabetes, cardiovascular disease, and certain cancers. The molecules that regulate these processes, including MIR135B, have also been implicated in the development and progression of these diseases. Therefore, understanding the biology of MIR135B and its potential as a drug target or biomarker is of great interest.

MIR135B is a non-coding RNA molecule that was identified as a potential drug target in the dbGaP project. It is located in the mouse oblique lineage and is expressed in various tissues, including fat, muscle, and pancreatic beta cells. MIR135B is involved in the regulation of glucose metabolism and has been shown to play a role in the development of obesity and insulin resistance.

One of the functions of MIR135B is its role in glucose metabolism. MIR135B is a key regulator of the intracellular glucose (Glc) level, which is crucial for the fueling of the cell with energy. MIR135B has been shown to interact with the protein Glucofusin, which is involved in the delivery of glucose to the liver for energy storage. MIR135B has been shown to regulate Glucofusin levels and is a potential drug target for the treatment of obesity and type 2 diabetes.

Another function of MIR135B is its role in insulin resistance. Insulin resistance is a condition in which the body's cells become less responsive to insulin, making it difficult for glucose to enter the cells. This is a key predictor of the development of type 2 diabetes and other metabolic diseases. MIR135B has been shown to play a role in the regulation of insulin sensitivity by activating the transcription factor ISGF-1, which is involved in the development of insulin sensitivity.

MIR135B is also involved in the regulation of inflammation. Chronic inflammation is a major risk factor for the development of various diseases, including obesity and type 2 diabetes. MIR135B has been shown to play a role in the regulation of inflammation by activating the transcription factor NF -kappa-B, which is involved in the production of pro-inflammatory cytokines.

In addition to its role in glucose metabolism and insulin resistance, MIR135B is also involved in the regulation of cellular processes that are important for the development and progression of obesity. For example, MIR135B has been shown to play a role in the regulation of mitochondrial function , which is important for the energy metabolism that underlies the development of obesity.

MIR135B is also a potential biomarker for the diagnosis and monitoring of obesity and insulin resistance. For example, MIR135B has been shown to be expressed in human obese tissues and has been associated with increased body mass index (BMI) and decreased insulin sensitivity. This suggests that MIR135B may be a useful biomarker for the diagnosis and monitoring of obesity and insulin resistance.

In conclusion, MIR135B is a potential drug target and biomarker for obesity and insulin resistance. Its role in glucose metabolism, insulin sensitivity, and inflammation suggests that it may be a useful target for the treatment of these diseases. Further research is needed to fully understand the biology of MIR135B and its potential as a drug or biomarker.

Protein Name: MicroRNA 135b

The "MIR135B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR135B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR136 | MIR137 | MIR137HG | MIR138-1 | MIR138-2 | MIR139 | MIR140 | MIR141 | MIR142 | MIR143 | MIR144 | MIR145 | MIR1468 | MIR1469 | MIR146A | MIR146B | MIR1470 | MIR1471 | MIR147A | MIR147B | MIR148A | MIR148B | MIR149 | MIR150 | MIR151A | MIR151B | MIR152 | MIR153-1 | MIR153-2 | MIR1537 | MIR1538 | MIR1539 | MIR154 | MIR155 | MIR155HG | MIR1587 | MIR15A | MIR15B | MIR16-1 | MIR16-2 | MIR17 | MIR17HG | MIR181A1 | MIR181A1HG | MIR181A2 | MIR181A2HG | MIR181B1 | MIR181B2 | MIR181C | MIR181D | MIR182 | MIR1825 | MIR1827 | MIR183 | MIR184 | MIR185 | MIR186 | MIR187 | MIR188 | MIR18A | MIR18B | MIR1908 | MIR1909 | MIR190A | MIR190B | MIR191 | MIR1910 | MIR1911 | MIR1912 | MIR1913 | MIR1914 | MIR1915 | MIR1915HG | MIR192 | MIR193A | MIR193B | MIR193BHG | MIR194-1 | MIR194-2 | MIR194-2HG | MIR195 | MIR196A1 | MIR196A2 | MIR196B | MIR197 | MIR1972-1 | MIR1972-2 | MIR1973 | MIR1976 | MIR198 | MIR199A1 | MIR199A2 | MIR199B | MIR19A | MIR19B1 | MIR19B2 | MIR200A | MIR200B | MIR200C | MIR200CHG